Frontiers, Not Boundaries

MicroMatrices Supports Compound Selection


13th November 2017

MicroMatrices supports compound selection in the following ways:

  • SpheroMatrices, a proprietary spheroid tissue microarray technology for de-risking drug safety/efficacy studies. Addressing translatability issues in preclinical drug testing via new analytical processes for profiling 3D organotypic models: spheroids, organoids, PDX 3D models. 
  • Specialist Investigative Toxicology services for risk assessment. Elucidating toxicological/therapeutic mechanisms through the application of integrated genomic/epigenomic/proteomic profiling (mRNA, miRNA, ChIP on chip, LC MS/MS) and pathways analysis.

Toxicological/pharmacological mechanisms are very often cell type specific. MicroMatrices specialises in high resolution cell type-specific analyses to characterise the toxicological response in different cell types in the tissue; please see our Services page for details/case studies.

This approach can facilitate the design of better in vitro models for assessing the relevance/ translatability of mechanisms identified in animal models to man.

 

‹ Back

WE WORK WITH YOU…

on an interactive, step by step basis. Collaborations can begin with pilot projects which can then be scaled up to larger research programs, according to your requirements.